Molecular Partners's DARPin programme offers partnering promise
This article was originally published in Scrip
Executive Summary
Molecular Partners would consider a partnering deal for the lead candidate from its DARPin product pipeline, which could be in the clinic by the end of the year, the Swiss biotech company's chief business officer Dr Patrick Amstutz told Scrip.